Chris Chu | Johnson, Spellman & Associates, Inc., IR |
Dr. Jennifer Bath | President and CEO |
Lisa Helbling | Chief Financial Officer |
Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to ImmunoPrecise Antibodies Fiscal Year 2022 Second Quarter Earnings Results and Business Highlights Call. At this time, all participants are in a listen-only mode.
Following the presentation, we will answer pre-submitted questions. [Operator Instructions] I would like to remind everyone that this conference call is being recorded today, December 13th at 4:30 Eastern Time. call Chris the turn now over Chu. to I’ll Mr. please go ahead. Chew,
Officer Bath, and Ms. Chief Financial pre-submitted speakers questions welcome. of period you their quarter A President today’s Lisa be call. on Dr. Chief will and Thank answering ImmunoPrecise; followed Jennifer and by Q&A remarks. the of Executive Helbling, summary follow will the Officer closing
remind following I have future Before asked activity, results, by forward-looking its are to the results those begins, actually of would events read statements. these statements, future several forward-looking I by about other -- with assumptions been risks that levels today that Safe Bath actually by plans, achievements company from remarks regarding Dr. to Harbor statements goals intentions, ImmunoPrecise contain there materially performance, obtained will everyone like were differ ImmunoPrecise expectations or and statements. preparing forward-looking and or and developments. the In made or current ImmunoPrecise
As Analysis you are www.sedar.com cannot a statements section Management and on to the undue place and investors will not on them. www.sec.gov. and at to of guarantee forward-looking reliance statement at information potential consequence, Discussion forward-looking that refers cautioned issued materialize current any today and the ImmunoPrecise and its company EDGAR
a the ImmunoPrecise Bath. events as like to Forward-looking laws, whether now undertake not does to update conference or as maybe December of forward-looking otherwise. over Dr. ImmunoPrecise’s obligation statements required statements any new expectations would represent by of XX, XXXX. securities turn information, I any as to result Except future
filled have year-to-date for period Thank IPA. you, This reporting been inspiring Chris. and energy and
as the been biotherapeutics in power grow the about result of scientific cast a and COVID to and life and backdrop many building world with saving result, the of has on industries. technologies aided change degree regulatory, transformed that ago, our clinical public We for the in therapeutics reality reality capabilities, to excuse the on been most has Only an Omicron me, it Omicron as As a threat open has relatively industry, in pandemic. and translatable catalyzed and importance eyes an IPA are direct in a as been understanding have bright has commercial This a onto new this world’s our awareness continues pandemic. in light U.S. as tremendous of technological COVID-XX for part the doorstep. COVID antibody settling reported in the is industry the Subsequently, mild. was the of industry, days to cases that sustainable a awaken the general
been ability even therapeutic Omicron. Omicron efficacy, and/or may flooded products Delta. of the Eli that as reports variant Center neutralizing regarding reported In of antibody now Sheba dual studies their with media Pfizer dose. indicate to concluded it with times combo is clear meantime, thus booster cases X Fred there dual and -- independent earlier treatment, who regarding Omicron Omicron individuals XX% were fully that had decreased Lilly the resist structural noting their potential both vaccinated of statement modeling those conclusions antibody has in its three against vitro was a from Regeneron antibody from probable of received loss in released both shots had that is Center that about antibodies. similar Cancer in Hutchinson than that effective protection a Pfizer and Israel Medical less Research of were at far the researchers over close people vaccine of such the XX% However, where these and the the were the companies against And Further,
retain to by induced well these of the has of thus believe time, testing variants understands that as is over as that have much well efficacy our path since variants was numerous incorporation vaccines true of by lose risk engaging IPA’s when specifically against anticipated escape including mutations. scientific we stated the our PolyTope would into genome. call action human of SARS-CoV-X many we therapies cocktail emerging emergence has efficacy designed the pressures it and SARS-CoV-X in those specified varied less and to epitope it these heavy selective synergistic all as We of belief lift, of accomplished continued far everyone of therapy was this activity, and regime. as SARS-CoV-X but that we mutations Likely and vaccination, relevancy this. Yes, mechanisms and concern, targeting to-date immune due limited at on to a of As borne system, non-overlapping the variants interest. This
PolyTope mutated possible highly Based generation against anticipate fact, it’s in as is well. the that efficacy variants only concern to-date. on therapeutic anti-SARS-CoV-X will In against activity sequence of retain Omicron IPA’s retain PolyTope first the all and structural we to that variant, analysis, silico
we variants As observed vitro models identified in with have other previously. concern all in of
the the and empirically not therapy, by producing technologies, and potential level Omicron, sustainable many antibody this to Wall PolyTopes COVID. small that against now a that the high platforms The helped calling innovations diversity of neutralization edge conducting as a a our Xrd, published of the profile, their and resulting advances lead scientific produce in have technology result. indicate IPA Initial mid-January. that of same of rigor enormous dispute sequence messenger national our to to scientific the Omicron. evaluate the did opportunities expansions new of take beyond MS. companies an far the with December one article profiliable readily even IPA of of have COVID at continued for is development and over infectious Talem emergence science studies significant expected hope led article is as from Talem had technology ImmunoPrecise the to and for anticipated concur partnerships functional powering vitro time. and ceding binding showcasing from by real we the that story, with and to products. important medical We IPA -- crisis the potential of magnitude It opportunity which the in to leading paths, that requires raced is industry and industry extend most build has advantage author while other result cancer The on was To and as ongoing and COVID. opportunities of went for that technology the industry, important, Given that vaccine even transformation during point, Street this technologies importance which the Journal applications, a experience, is occurred, promise part of is the arising on which and sheer company, pandemic on that data diseases in opinion treatment illustrate health our COVID-XX large the Equally to is of is and our of attention these based Well, studies it only RNA and representative the an defines insight disease develop to more in tackle collaborations tackle vaccine
to that partnerships expansion animal same IPA expand only technologies our for less our companies leverage unique Talem our repertoires regulatory can and routes potential focused to therapeutic and unique targeted poised as few partnership. internal categories meet since cornerstone into serve diversification begun clearly but a rapid companies sector revenue to rapidly initiatives recent delivery and partnering improve manufacturing enable with enable selective shifting therapies our collaborative focusing these some the of as CRO based antibody assets. our therapeutics. both new the cutting and development, quarters not leading RNA to organic growth, offer for hindered opportunities on partner approvals methods a use We’ve landscape. of past and discovery diverse and both edge patent pipeline preferred design, they these -- continue And platforms production and Our also possibly acid on expand management new to and potential benefits commitment and continued expertise as disease. is beyond be technologies partnerships. attention for in infectious development our by for utilizing nucleic ongoing on over leveraged novel to needs far technologies R&D We more research growing we efforts the our delivery negotiating delivery, partnership into those through With CRO
and projects XX for assistant XX We’re in IPA Oss new to Europe the hired top two happy Canada not research Netherlands IPA and to Canada we discovery top growth serving announce the the and at previously we continue quarter, to initiatives protein biopharmaceutical site at the team Further technicians expression we’ve leader sites, initiated in companies additional grow site the new we two In antibody a served. scientist at and first laboratory support a the project had Victoria. which companies, globe. and the across our
For Canada will will asset Expansion our fiscal is animals Care end IPA’s Regulations. increase the also disruption The cause not date increase CRO and renovations and quarter, of The aspects capacity of Canada Council will house care the renovation to year Health of used The The the the and compliance for both ongoing Guidelines both completion Agency wild with this The estimated facility. expansion barbarian and and facility on business. Animal X in footprint of the animal our began renovations Biosafety type facility’s double Canadian quarter. our development. its current in operations Level Talem IPA facility Public of our any to transgenic fourth for IPA’s early
IPA’s taking and events is designed has quarter fiscal September Conference tied new new we in-person the as architecture of entitled in that marketing sense database a phased Commercialization team scheduled has the result data But the an have evaluated Brand ensure competitive beginning Engineering targeted marketing Master urgency has since shift been be IPA’s of Both a where an in pandemic. a the place. each resource year. business, performance taking activities to for Maintaining IPA positioned been marketing driven performance in that of marketing the order in-person securely normally initiatives edge. attend would the to virtually. to strategy revitalization grow San the the Us generation order Diego lead us development XXXX have As measuring Marketing in-person to held Multi-Channel the a annual and quarter. included and with taken October. compete the and been return. commercialization Relations and content conferences been third been Co-Marketing developed CRM. gain that rapid mentioned IPA which and Many in first fuel support of the we completely investments and approach, insights a with major opportunities with AI-powered growth scientific stepwise to into are enables had on Antibody before, and place place of a now for of is in allocation elements effectiveness with framework planning of this new assessing marketing and and month calendar conferences Campaign plan, software future our attended Challenge underway of lead at a in Further Eurofin week. Client will sales Other at QX real-time metrics together to to and with a and the win conferences
Talem Boston. Antibody underway in Engineering On Cell & holds of collaboration completion announced the owned be antibodies biotechnology year the a And host Talem against of Therapy Pierre across Xth, group that an discovered certain multi-target and jointly discovery Summit IPA private jointly Summit, Talem diverse Talem’s planning and Protein following pharmaceutical selected antibodies relationships will sector. pharmaceutical collaboration strategic of expand research is antibody at have to This through develop developed Talem’s French receive in payments. contingent the October to which upfront the exclusive portfolio each we held with In therapeutic to targets Fabre group. to research is adds May worldwide and for the discover next annually multiyear be to turn, an will to aim different to target novel by and license across nine to this largest The eligible would Together second companies collaboration help is interest of variety Fabre. up oncology. also program, in research the downstream It obtain expected the of antibody. targets. Pierre Pierre Fabre, antibody those Additionally, option specific
support for quarter, further and responsible a a related hires the of in clinical be advancements will Fabre support addition the Both partnering identification Pierre commercialization as licensed, if director. evaluation addition, assisting jointly and scientific In new development, well were non-clinical preclinical and two antibodies. experts also targets. writer including of study of discovered to This our activities, the will programs, new to hired as past internal with
a supply to our programs in slightly TATX-XXprogram COVID throughput disease to for are functional mode some we best Although, recent of share and of of high neurodegenerative disruption cardiovascular select anticipated Talem happy of performing characterization program are action. and due we materials to that related are the in clones delayed and reagents, finalizing disease oncology in the our our TATX-XXX the
For TATX-XXX, ADC we approaches. in antibody currently are that known drug for performing proof-of-concept studies vitro as are conjugates
with Regarding oncology, to functional our we as we our Twist, collaborative candidates. analysis the in a potential target seek are TATX-XXX, finders use program with lead nominate subjecting to
clinically Twist leads two antibody mode develop full relies approach As aim the to therapeutics. intended to different of transferring we mechanisms, fit optimization on for categories two or clinical
the announced academic Technology. IPA, Radboud development start COVID. the the partners, and and naturally have and partners This have before integrated As of example with they on which SARS-CoV-X are University Center COVABELP we expertise another the nanoparticles. therapeutic focused delivered intranasally, enriched at two the fragments, antigen University nanomedicine Dutch yet SARS-CoV-X fight The against is specific spike binding smallest the The supporting infrastructure joined a leveraging of is new our strengths, successfully antibodies, into targeting of while of consortium of VHH capabilities This have protein our year, VHHs occurring in along the opportunity the we additional identified just how Eindhoven Medical consortium
anticipated confirmed immune virus have aggregation bind lungs, the the of clearance host directly targeting to is We subsequent fact do research batches by that the system. in by and ability nanoparticles tremor. VHH SARS-CoV-X Apart to now initial the from nanoparticles virus deliver this induce to approach
TATX-XXX applications in and XXX, virus, potentially already in our simultaneously to treatment been and cocktail; to neurodegenerative more antibody our conserved immunity Other antibody sustainability cell antibody several panel this include, in autoimmune compounds in Notably; in be our diseases host on epitopes. one leading product. might infection proof-of-concept TATX-XXX, the well tumors. as TATX-XX, other XX It to its program, for higher generate parallel also an targeting is some antibody disease. interfering with Talem Talem, have action somewhat that patient approach verification. immune as the programs oncology our working currently mentioned by more of selecting our also clearance, panel compared distinct and significantly TATX-XXX, relies PolyTope use cardiovascular the for advanced cardiovascular aggregates virus oncology, oncology, As TATX-XX in disease; for mechanism believed disease and oncology which directly viral is this by of TATX-XX, to for on response, programs, and leading inflammatory a for a solid programs vitro vaccine to now neurodegenerative XX stage for disease and one and fragments, call. -- TATX-XX of Through are entering in for advanced more TATX-XXX of
have dozen particular for screening antibodies ideal a one functional prioritized assets help around the will that us TATX-XXX, we identify based ADC for For therapies.
study high around separate functional of lead strongly was target, XX% a our able that the desired the While candidates outcome. are to throughput which activate confirms
XX, The For XXX, earlier steps with TATX-XXX antibody now crucial formation. throughput are step uptake of plaque candidates lead be interfere stage endothelial and selection. LDL by for in XX with at atherosclerotic their XX selected ability XXX, different analyzed over cells, pools lead XX, a will high to programs, specifically
assess continued our next by parties with meetings, regarding and In of remains with couple conjugates. potential research On Abthena use Oss. negotiation together currently oncology. of service antibodies an The site varying optimization numerous our of expertise COVID-XX the assets, workflow to further the grade biopharmaceutical preclinical anticipated assets, ADC we’ve functional to degrees appropriate including is our team requests in two an the of its and peers, clinical of capabilities Talem the leveraging and three as platform its bispecific in antibody continues the active activities entered are of working yet weeks. and energized attributes to applying MTA cross Goals of production the governed also sites partnership focusing receive drug scale partners recent team research clients, are the TATX-XX, approach the Netherlands undisclosed on bispecific for discussion and R&D, format, the partnering engage in each facilitate as antibody unique bispecific these targeting out and/or XX. the as antibody into non-neutralizing potential capabilities are optimize licensing in in purification from expected antibody company vivo streamline suitability but only Talem of production program. in analytical our internal mainly site in and assays the not collaboration an research IPA diverse this transfer has for will of will combination scientific proof-of-concept of for also batches of in more studies. Utrecht to Our Results therapies. a for of larger and XXX and
for having proof-of-concept regarding licensing platform, any them do bispecific without have addition bispecific to platform to our In restrictions the allows IP generated customers a a who clinically to access data. in of generate validated prior not service
memory sequencing, recombinant and Next XXth, machine leaders B in cell grant will B antibody production. the Council from B with IPA learning continuous one are cell, high to to and grant Assistance Canada platform kind an Generation throughput protein next-generation of the a our plasma Antibody effort End-to-End of workflows financially of ongoing the of Platform We support on repertoire in Development Research pleased Canada cell titled announce Unique industry the an Research was in B development single National Industrial of discovery, integration Discovery cell that November through awarded Program a remain discovery
program escalation enabling and For higher application. after which studies, available. mortality entered revealed Initial with initiated administration is the and preclinical clinical clinical toxicity dose no our reviewed PolyTope’s IND into as rat were for dose by study from of ten-fold safety SARS-CoV-X signs of the final stage anticipated data round concentration observation of work. levels FDA of a were first we the the
are month. body addition, later our request by a for discuss to full protocol, temperatures screening variant observation. to generating in measured deviating but With study escalation results. this, Lisa to those to of cocktail FDA dose by call first tools our parallel, the In no and requested we during tune report study the to end this FDA, with line is as antibody be contact The in-human we In the like in Omicron are expected fine have to expect post-dosing available our the quarter’s also were to available highly workflow, in direct I’d data sets over response with the turn January. the mutated financial
you, Lisa Canadian numbers results, then touch to Jennifer, financial good IPA’s and upon referred financial noted, IPA’s Thank and CFO. in will afternoon, are dollars. liquidity results. all Unless quarterly the address Helbling, I’m I everyone. otherwise our year-to-date
driven its $XXX,XXX As a the in basis ended X.X% than to for XXXX, strategically scale October shop -- notable three during are the On these CRO the periodic by and decrease $XX,XXX in company’s revenue Jennifer through XXXX, a quarter on rather $X,XXX,XXX accounting year-over-year decrease. compared the large investments of a catalog recently for capitalized. the Talem website. month project or therapeutic mentioned, antibody developing of investing three sales the months XX, the large and The increased is research From a $XXX,XXX period. significantly on a sale owned revenues antibody online expensed an variety increase assets. launched achieved Product product sales revenues, background, company $X,XXX,XXX in company perspective,
improved As year and system a previously company implementation fiscal reported, reporting eight the in ERP its NetSuite XXXX. past full its a new during systems, financial the quarters, accounting during culminating of
new caused for the restrictions research company variance the and miscalculation new an This April miscalculate eliminations and travel complicated the first primarily but to caused revenues to That, with quarters sales transactions, intercompany to procedures the ended implementation was year. to its last development by of for full processes along year, related system of COVID-XX. notable Talem. used XX, While due was XXXX, in immaterial significant implementing three
account last XXXX had of third miscalculation, ended period The for revenues, first two would revenues Taking the year’s in over three-month corrected prior XX.X% quarters XX, the of October $XXX,XXX total overstated year. which were year or quarter. have into increase last the
you $X.X and see gross quarterly gross was million, company’s of detailed interested information to with in margin gross those profit pro a The of XXXX, information, the XX% you decrease. results. For forma company’s a gross MD&A the profit in million $XXX,XXX profit XX% more summary in margin, compared $X.X profit can a
system, in be lower up has with gross compared $XXX,XXX, aimed XXXX. the expenses increase the relates operating $XXX,XXX compared employees impact There The on align related the With higher these options were being is payment goals. expense expenses, company period. company $XXX,XXX of plan discuss research the antibody from granted order is total the the Talem therapeutic overhead of for and The expense the primarily company’s in the the to The $XX,XXX undertaking to the sales. P&L implementation million are Share allocating million increase vesting expense $X.X due this allocation option the section we to to million. over of owned over to its first million, increased improved development increase. from $X.X in $XXX,XXX investments on A $X.X $X cost not additional in insurance margin that expense of costs cost $XXX based new was XXXX, to method in the it to $X.X method, expensed Research from four from that variances listed due of an D&O ERP stock I’ll overhead premiums and company’s increased and XXXX, to were expenses to strategic new being to With profit of largest NASDAQ. reminder, -- going expense operating to cost XXXX, of of sales. expense. primarily forward. does make development moves in quarter million expect shareholders in expense company assets. its The
of lab the employee’s primary administrative time. the million other other income expense salaries compared $XXX,XXX. compared compensation, decreased in income for in compared benefits $X.X XXXX, nil Other pay an leadership and routine strategic income to increases XXXX, in relates compared of $X salaries XXXX. million $XX,XXX to company But for quarter, XXXX. new and of Finally, related and or in cash roles XXXX, $X.X the increase is million XXXX, recorded expense subsidy included million, director COVID in million including other reason the by of of and a were cost expense, VP allocation income from example cost $X.X is sales. reduction offset of The of expense reduction of $XXX,XXX Marketing for Relations. of Client to of VP These $X.X An the receipt $XXX,XXX in allocation of wage related COVID a increases in in in in income grant overhead to to to the
to Finally, interest company quarter, Net XXXX. $XXX,XXX Program compared compared loss, expense $X loss XXXX, in in for of from the loan and in XXXX QX in the $X,XXX other is result net $XXX,XXX subsidy U.S. recorded to company in of forgiveness the receiving the a an Paycheck a Protection a XXXX. partner million income of of
of result subsidy investment other the research and activities, D&O can insurance, income, in graph, and reduction waterfall seen grant a and As net a income the loss in the as company’s summarized a increase income. be can development in decrease on increase be
caution gain you reliance of measure upon adjusted Before XX, EBITDA. statements view EBITDA XXXX, months October depreciation the consolidated all that management’s EBITDA I the XXXX in a should and taxes, place financial accounting ended a million, the a XX, in earnings presented IFRS the EBITDA for I must reduction compared predominantly not operating of condensed for period EBITDA, undue $XXX,XXX and of read months XXXX, the October interest, investor Adjusted touch investor adjusted on a $X.X and was XXXX. adjusted earnings, of adjusted urge non-IFRS disclosures I to the before three loss company’s to amortization, million, of is six of is interim from $X.X in ended IPA’s which $X,XXX,XXX, increase insurance of on entitles discretion sell activity, its few prices time-to-time through the aggregate facility, gross the agreement common from costs $XXX,XXX having in during increased October the development, and company at and shares A an price & about term an up liquidity an agent established shares $X,XXX,XXX. transactions investments and income market the to negotiated will grant of subsidy at The H.C. aftermarket time sale. company US$XX ATM common Wainwright a at XXth, decrease the and equity its distributed research and of comments be capital of company in million. to Co. markets sales prevailing offering the of of
sell for XXXX, to stock the between this TSXV. on and time on and sales vary at no sale market, US$XX facility. the purchases ATM in required company the made of will NASDAQ be sales shares The be such, of today, not term million available during prices time. under of remains the any global On shares XX, is common Canada directly may company’s of common the will the October As facility over as made
the held of As capital of of company and October XX, million million. have $XX.X XXXX, cash $XX.X working
first cash activities operating the $X,XXX,XXX. was used the quarter, in During
equipment company made investing of of $XXX,XXX. purchases As the part activities, the
with projects, of company financing year, months and primarily compared the had revenues sales million of of difference and last subsidy include, same income to in the turn financial activities, from million change The company and an last income payment due loss Jennifer continues months to for This year, $XXX,XXX assets, were of $X.X million, margin million during period gross to $XXX,XXX Chris is visual stock months part NASDAQ cell year year $XXX,XXX. period being October made to consulting Similar expense X.X% revenue period and profit Last received $X.X lower six in related ended and the of year-to-date a antibody loss results. The million D&O related options, insurance options The prior and call employee common year. systematic investments and $X.X as align achieved the I’ll $X.X XX%. totaled owned October in back to that, to trend $X now the October received my graph, such As during fees XXXX the and Talem increase support than six been changes of the attention in related the million to the strategies issuing With profit year over six vesting to $X.X turn the $X.X and professional last research XX, of from lease the the Gross payments of for company professional for employees of assets. to average XXXX, months first the to XX, the elimination expensed increase previous increase XXXX year, not XXXX made improved of ended miscalculation XX, primary of listed revenues last and primarily October therapeutic on company therapeutic in company’s and to from antibody the goals. waterfall cost And of overhead occurred, to when year. Expenses with government quarter, the this and growth by XXXX. net forma related of notably six-month been last the six company’s The non-cash ended during year’s for expense the had XX, Non-cash months are months investments select XXXX. related million six D&O summarizing share-based six consulting million million, for revenues compliance, revenues company the payment with Talem would XXXX, and development would related of of October its lower and grant comments pro the XX, and partner to expense to grant my for up development subsidies. this smaller granting financial have $X.X If Q&A. stock profit for for a was the to of the million $XXX,XXX. $X.X share-based ended in the three-month Other lower revenues associated strategies I’ll in differences. income the research COVID-related increasing XX% intercompany cost have fees. net current overstated owned the These most year options a by shareholder gross in first to is B and XX% year-over-year. stock platform. the up the similar period. costs over value insurance allocation the margin to $X.X and other through compared $X.X million, in
Lisa. Thanks,
I would from spend Before any some investors. to the like time Jennifer adds that analysts and remarks, questions we received closing a little asking of
the announced conduct to question, for LiteVax. data studies prior is call, vaccine first and TRANSVACX the on preclinical studies additional earnings you the will when from expected? SARS-CoV-X received For you funding occur additional with When program the
Chris. you, Thank
proof-of-concept responses it immunogenicity to from demonstrated system study LiteVax, For to so, had TRANSVACX findings, those immunogenicity, then mixture familiar significant to of antibody strain conduct if funding immune for also previous expose an previous fund IPA with concern. agree challenge an That the immunogen variants further relevant development. if to could further with proprietary agreed adjuvant that aim to of on accelerate SARS-CoV-X was study study you studies and to company TRANSVACX Syrian to the the be study, follow-up to to vaccination that an hamsters in and generated several based epitopes commit a combined using further original functional from the those with and received of determine to a and named not funding IPA the
finalize So study screening second recently of through the funded collaborative in CRM we reactivity TRANSVACX. did immunogenicity LiteVax, with pigs the regarding our vaccine
grant showing that We clinical If a by was protein that are data encouraged study a are proprietary efficacy immune responses, in as serum CMS upcoming same swine using with the benchmark combined studies neutralizing subsequent our that the supported was CP immunogenic vaccine adjuvant. to SARS-CoV-X in similarly then hamsters. will also stage by includes immunogen adjuvant verify virus mixture LiteVax’s challenged the able TRANSVAC reactivity
had a not are Twist an or Where while. collaborations are we’ve those collabs? on Next, Genmab we update in
question. Yeah. Good
those Twist during an regarding update we collaborations, this call. collaboration on provide So earnings the did
completed from vivo updates the one in on program can now Genmab, general animal see website has that For Talem this our studies.
approval this are we program. However, waiting collaborative share from Genmab details on more to
today able until we’re So to their that’s we have provide all permission.
IPA seems Can of for And the today, poster timeline that test University made the about trials. ready Victoria for on the a and public COVID saliva you elaborate commercialization? future trials
Sure.
agree from tests. the will system the third-party the that upon The encouraging, of are that it’s of we the were presentation human a with and the have we timelines, and they and presented do others understand results the with COVID outcome awaiting very Canada, IPS cued UVic, the UVic, largely poster those saliva program with direction in test involvement while validation on that So, in from the the level sample. be dependent
And would update resources is Pierre focus -- you do APA how and take regarding for the how collaboration, Fabre many the that what IPA? and first when timeline or much the expect
in a We’ve the few times heard last here question that week.
a So we’re really happy light this. to little on shine
early Pierre work So selected executed have the a work plan Fabre, the and groups October, the finalizing Pierre anticipates then target Year. in the has in with the research New month commencing joint which and Fabre was this two which now collaboration therapeutic research first committee, laboratory by the created agreement
results to different other lines intensity, large And actually the performed no, continual only the performed we regard results, intensive workflow not So, facilities would and internally next make XX annually we levels obviously, under to in conduct summer. at and programs assessment. reminder come that companies, its antibody our any has go decision with of advantage programs Pierre pipeline but cost, that something than think I our over partners. information those does The along its is expect enable of terms that’s of more go or a therapeutic collaborative over that we’re off, and that the or IPA campaigns capacity they’re the in data a also for work Fabre other resource any there’s distinctive looking with not research clients at of Talem with good data for where discovery and the control really as first critical program, something
And call, or increased timelines changes interest any for from does the conference question today’s in to lead last Great. potential Omicron partners?
Okay.
to will, So, in computational we’re analyses earlier on we presentation, empirical be done, that TATX have data support Omicron. as our will impacted quite mentioned we by although, for we the not timelines expectations. optimistic development the Based negatively seek that our
So preclinical a are Omicron, antibodies -- clinically even a a by SARS-CoV-X as neutralizing showed we escaped urges percentage which previously, for of directly multi-targeting need significant actually the encouraging. respect, of clinical IPA’s very recent of clear and that publication stage laid approach more the and really the is stage the neutralization PolyTope demonstrates behavior of interest products Omicron that advantages approach. toward the variant N In the FDA
Great. today. were to our And now and Jennifer? fiscal or thoughtful concise you answered some either strategic and script I the MDA. and in thank hope into with in we the submitting your with on remarks closing for that, Q&A questions move planning. they will We the year current insights
Thank Sure. you, Chris.
be and its to And work course, our of this that say display the first planned appreciative have our has unique the that thank So, critical of exciting patience and the advance own we every our partners, I’ll first been put in we’d the the like have step employees, of our way. pathway on truly for IPA’s won’t with customers, to hard along continuing to we’re strength set the goals. and IPA. mission execution order that of challenges on and and foremost, journey shareholders
earlier, today’s However, journey. decisions biotherapeutic this has from of the as served are in actively transforming call, start that evolutionary space IPA that we very to the inform the pressures noted our
sources continue that progress early win only Our mass. and new and pace broaden global new we allow to not to have necessary scale, marketing still days its and also to business, critical us at our business at generation, our we for a to in scaling close success that but accelerated clear to of footprint of infrastructure despite is the will revenue a tackle fact base. ramp are an assembled leadership the and pathway as customer now in and on compete new we sales the We’ve new resources critical
one under industry to of to proprietary manufacturing. an we developing in repertoire We candidate in-house our With to Talem add also continue technologies own as discovery excited in-human see first discovery are potential our progress. of continue trial roof and are antibody to leader wholly an assets and
day. monetization to you come. developing intended, have produce future of the years have IP us As which assets for own and will we that Thank in broadest our will taken great command the opportunities a provide these of -- for your with rest we
concludes This today’s conference.
for at your participation disconnect you may this day. a your have great You Thank time. and lines